Apixaban is known by its brand name, Eliquis [1].
What other drugs are used for similar conditions?
Eliquis is an anticoagulant used to prevent blood clots. Other anticoagulant medications include warfarin (Coumadin, Jantoven), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) [2]. These medications work in different ways to reduce the blood's ability to clot, helping to prevent strokes and other serious conditions [2].
When does the patent for Eliquis expire?
The original patent for apixaban expired in the United States in 2026 [3]. However, there are other patents that may extend market exclusivity beyond this date [3]. DrugPatentWatch.com tracks these patent expirations, which can impact the availability of generic versions of the drug [3].
What are the risks associated with apixaban?
The primary risk associated with apixaban, and other anticoagulants, is an increased risk of bleeding [2]. This bleeding can be serious or even fatal [2]. Patients taking apixaban should be aware of signs of bleeding, such as unusual bruising, nosebleeds, or bleeding gums, and report them to their doctor immediately [2].
How does apixaban work?
Apixaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, a key component in the blood clotting cascade [1]. By inhibiting Factor Xa, apixaban reduces thrombin generation and prevents the formation of blood clots [1].